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Methamphetamine abuse is a major health concern that has been associated with adverse
effects such as behavioral disturbances, impaired memory, and cognitive deficits. Chronic use of
methamphetamine has been found to cause persistent changes in dopamine receptors and
DARPP-32 expression in the rat striatum. Because methamphetamine use has been associated
with memory and cognitive impairments, chronic effects in memory-related regions should be
thoroughly examined as well. The current study investigated the long-term effects of
methamphetamine self-administration on D1 receptor and DARPP-32 expression on the
subregions of nucleus accumbens, hippocampus, and perirhinal cortex via immunostaining. I
expected to find decreased levels of D1 and DARPP-32 expression in subjects that selfadministered methamphetamine compared to saccharin. The results for D1 receptors were
inconclusive due to technical difficulties. DARPP-32 expression results did not show a
significant effect of methamphetamine. The findings suggest that methamphetamine did not
cause any persistent effects on DARPP-32 levels. However, the experiment had some important
limitations that should be taken into consideration.
KEYWORDS: immunohistochemistry, methamphetamine, dopamine D1 receptors, DARPP-32,
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CHAPTER I: INTRODUCTION
History of Methamphetamine Use
Amphetamine (AMPH), a sympathetic nervous system stimulant, was synthesized in
1887 by a German chemist; however, it was not studied comprehensively until the 1930s.
Because AMPH provides relief by reducing nasal decongestion, it was used for the treatment of
asthma in 1932. By the 1940s, AMPH was already being used in treating many conditions
including narcolepsy, hyperactivity, tobacco addiction, low blood pressure, schizophrenia,
morphine addiction, and many others. Methamphetamine (METH), an AMPH derivative, was
synthesized in 1893 by a Japanese pharmacologist. However, METH was not commonly used
until World War II when the drug was made available to the armed forces to enhance
performance and alertness by the United States, Germany, and Japan. In the U.S., AMPH was
available as an over-the-counter medication until the 1950s and was still widely prescribed for
depression and obesity in the 1960s. The first illicit METH laboratories emerged in 1962 in San
Francisco. After the use of METH increased significantly in the mid-1990s, when it was
illegally produced on a massive scale by underground labs on the West Coast (for an extensive
review, see Anglin et al., 2000), it became a major public health concern (Wermuth, 2000).
Although METH has been legally available as a pharmaceutical tablet called Desoxyn since the
1940s to treat Attention-Deficit/Hyperactivity Disorder, narcolepsy, and obesity, it is primarily
sold illegally for its recreational use (Scott et al., 2007).
Prevalence Rates of Methamphetamine Use
METH abuse has been described as an “epidemic” in the U.S. as the prevalence rates
significantly increased through the early 1990s (McCaffrey, 1995). Between 2015 and 2018, 1.6
million adults reported past-year METH use in the U.S, and approximately half of these
1

individuals had METH use disorder (Jones et al., 2020). Among adolescents, prevalence rates
show that compared to other illicit drugs, METH use is relatively low. A national survey called
Monitoring the Future reported that the annual prevalence rates in 2018 were 0.4% for 8th
graders, 0.4% for 10th graders, and 0.5% for 12th graders. These rates were reported to be the
lowest recordings since the first measurements were taken in 1999, which suggests an overall
decrease in METH use among adolescents (Lloyd et al., 2019). On the other hand, emergency
room visits associated with METH have increased from 11,002 in 1996 to 102,961 in 2011
(SAMHSA, 2014). In addition, Gonzales et al. (2018) reported that the percentage of adolescents
who were admitted to Los Angeles County drug treatment centers with METH being their main
drug of abuse increased from 8% in 2002 to 31% in 2005. More importantly, it has been found
that METH-using youth reported greater psychosocial dysfunction and were less likely to stay
drug-free throughout treatment compared to the non-METH-using youth (Rawson, 2005).
Although METH use has been widely studied in adults, we know relatively little about its acute
and chronic effects on the adolescent brain (Buck & Siegel, 2015). Considering the highly
addictive nature of METH and the potential brain alterations that it can cause to the developing
adolescent brain (Spear, 2000), it is important to understand the chronic neurotoxic effects of
METH use both in adulthood and adolescence.
Physiological Effects of Methamphetamine
METH is a central nervous system psychostimulant that can be smoked, injected, or
taken orally (Gonzales et al., 2010). Acute effects of METH on the autonomic nervous system
include hypertension, tachycardia, hyperthermia, and increased breathing (Scott et al., 2007).
The desired cognitive effects of METH include increased energy, alertness, positive mood state,
decreased appetite, and elevated self-esteem (Rawson et al., 2002). These effects are produced
2

through heightened dopamine (DA), serotonin, and norepinephrine activity in the brain (Anglin
et al., 2000). METH achieves this increased activity by stimulating the release of freshly
synthesized catecholamines while also blocking their reuptake. Because of its similarity in
structure, METH enters the presynaptic neurons through the DA, noradrenaline, and serotonin
transporters and reverses their endogenous function, which redeploys monoamines from storage
vesicles into the cytosol and releases them into the synapse. The released monoamines stimulate
the postsynaptic receptors in the major dopaminergic, noradrenergic, and serotonergic pathways.
Dopaminergic regions have been associated with the euphoric effects of the drugs.
Noradrenergic regions have various functions such as arousal, memory consolidation, and
cognitive processing. Lastly, serotonergic regions are involved in respiration, pain perception,
and higher-order cognitive processing (for an extensive review, see Courtney & Ray, 2014).
Dopaminergic Pathways
The midbrain DA neurons are associated with behaviors that are involved in reward,
cognition, and motor movements (Haber, 2014). Some dopaminergic neurons originate in the
midbrain ventral tegmental area (VTA), which plays a central role in the processing of rewarding
stimuli and drug addiction (Lupica et al., 2004), and their axons extend to several parts of the
brain through several dopaminergic pathways. The vast majority of the DA in the human brain is
transported through four pathways including mesolimbic, mesocortical, nigrostriatal, and
tuberoinfundibular pathways. The mesocortical pathway includes DA neurons that project from
VTA to the prefrontal cortex (PFC). The mesolimbic pathway, also known as the reward
pathway, projects to nucleus accumbens (NAc), amygdala, and hippocampus (HPC), (for review,
see Stott & Ang, 2013). The mesocorticolimbic system (VTA, NAc, and PFC) represents a
mutual substrate that plays a role in the reinforcing properties of drugs (Koob, 1992) and the
3

development of behavioral sensitization (Blum et al., 2012). Behavioral sensitization is a
phenomenon characterized as a progressive increase in locomotor activity and/or stereotyped
responses to a stimulus (Robinson and Becker, 1986). The early action of AMPH and METH in
the VTA is thought to be a critical event for the initiation of behavioral sensitization. Unlike the
other major dopamine pathways in the mesocorticolimbic areas, the nigrostriatal pathway
originates in the substantia nigra and projects DA to the caudate nuclei and putamen of the
striatum (Haber, 2014). Lastly, the tuberoinfundibular pathway transmits DA from the
hypothalamus to the pituitary gland, in which DA functions more like a hormone that inhibits the
release of prolactin rather than a neurotransmitter (Scott & Ang, 2013).
Drugs alter activity in the DA pathways in numerous ways by altering neurotransmission,
which is a complicated process that involves the synthesis and storage of neurotransmitters, their
release in the synapse followed by binding with pre-and post-synaptic receptors (Giros et al.,
1996). Some drugs such as heroin, morphine, and other opioids increase DA activity by binding
to opioid receptors located on the GABAergic axon terminals. This binding inhibits GABA
release onto DA neurons which leads to enhanced DA activity (Johnson & North, 1992). Other
drugs, such as cocaine and AMPH, elevate DA levels in the NAc by directly increasing DA in
the synapse and the time DA remains at the postsynaptic site. Cocaine achieves this action by
blocking the presynaptic dopamine transporters, while AMPH works through increasing DA
release from the synaptic vesicles (Ritz et al., 1987; Bunney & Aghajanian, 1978). As described
earlier, METH increases the amount of DA at the synapse by both stimulating the release of DA
and by partially blocking the reuptake of DA by presynaptic receptors. Methamphetamineinduced neurotoxicity is evident in all dopaminergic pathways with the most notable one being in
the nigrostriatal pathway (Cass, 1997).
4

Dopamine Receptors
Neurotoxic effects of METH are thought to result from excess DA release and the
dysregulation of DA control (for review, see Ares-Santos et al., 2013). Although METH
influences DA levels through multiple mechanisms, the dopamine transporter (DAT) may be the
primary location of the action. In a study by Giros et al. (1996), DAT knockout mice did not
show any locomotor activity or dopamine release and reuptake after receiving either cocaine or
AMPH, which suggests that DAT might be a major site for AMPH derivatives’ action
mechanisms. Acute administration of METH has been found to cause a rapid decrease in DAT;
though, this decrease was reversible in less than 24 hours (Brown et al., 2002; Fleckenstein et al.,
1997). Similar to DAT knockout mice, pretreatments with DA uptake blockers (Stephans &
Yamamoto, 1994) and DA receptor antagonists (Patrick et al., 2011) were found to attenuate
METH-induced DA efflux and DAT loss.
Dopamine transmission in the brain relies on the activation of G-protein-coupled DA
receptors. DA D1 receptors, one of the five DA receptor subtypes, are widely found in the brain
with the highest levels found in the NAc and caudate putamen, which is comparable in both
human and rat brains (for review, see Cadet et al., 2010). METH-induced neurotoxicity as a
result of increased DA is thought to be a result of DA D1/D2 receptors. A study by O’Dell et al.
(1993) found that pretreatment with both DA D1 and D2 receptor antagonists was effective in
preventing METH-induced striatal tissue damage and DA overflow. In addition, D1 receptor
knock-out mice showed decreased DA tissue damage, dopaminergic neuron loss in substantia
nigra, hyperthermia, and neurotoxicity after repeated injections of METH (Ares-Santos et al.,
2012).
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Several subcutaneous administrations of METH (15 mg/kg) have been shown to reduce
D1 and D2 receptor sites in several brain regions with the highest impact seen in substantia
nigra, followed by caudate-putamen, NAc, claustrum, entorhinal cortex, and amygdaloid area
(McCabe et al., 1987). A previous study on chronic effects of AMPH (3 mg/kg), administered
intraperitoneally (i.p.), during adolescence and adulthood showed a persistent D1 receptor
reduction in the medial PFC (Kang et al., 2016a). For adolescent subjects, this reduction was
associated with an increase in approach behavior, anhedonia, and depression- and anxiety-related
behaviors in adulthood (Kang et al., 2016b). However, a similar reduction was not observed in
NAc (Kang et al., 2016a).
Phosphorylation of DARPP-32
Dopamine and cAMP-regulated phosphoprotein (molecular weight = 32 kD), DARPP-32,
was discovered during dopamine signaling studies (Walaas et al., 1983) and has been extensively
studied to understand its mechanism of action. DARPP-32 is present in large amounts in
medium-sized spiny neurons in the striatum (Ouimet et al., 1984) and is co-localized with DA
D1/D2 receptors (Langley et al., 1997; Rajput et al., 2009).
DARPP-32 is essential to dopaminergic activity and efficacy (Fienberg et al., 1998). The
activation of D1 receptors by DA activates adenylate cyclase and increases cAMP levels which
trigger the initiation of protein kinase A (PKA) eventually leading to stimulating the
phosphorylation of DARPP-32 at threonine-34 (Thr-34). Phosphorylation of DARPP-32 at Thr34 alters its biological properties, turning DARPP-32 into a potent inhibitor of protein
phosphatase 1 (PP-1), which controls the activity of multiple significant substrates such as ion
channels, pumps, and transcription components (Greengard, 2001). Thus, investigating DARPP32, because of its ability to modulate the PKA and PP-1 activity, is essential to understand the
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mechanism of action of DA, its interaction with other neurotransmitters, the behavioral responses
to drugs of abuse and other stimuli (Greengard, 2001; Svenningsson et al., 2004) as well as PFC
function (Yger & Girault, 2011).
DARPP-32 may also be required for the actions of drugs of abuse. For instance, a study
by Zachariou et al. (2006) found that DARPP-32 knockout mice do not display the typical
behavioral effects of cocaine such as increased locomotor activity, indicating that
phosphorylation of DARPP-32 may be required for the cocaine’s mode of action. Similar results
were found for morphine’s effects as well. Borgkvist et al. (2007) observed that DARPP-32
knockout mice did not show an increased motor behavior after an acute morphine injection.
However, DARPP-32 might not be required for rewarding properties of morphine as there were
no differences between DARPP-32 knockout mice and controls in conditioned place preference
(Borgkvist et al., 2007), which is a classical conditioning paradigm designed to measure “druginduced motivational state” (Scofield et al., 2016, p. 821).
Several studies on drugs of abuse found that DARPP-32 plays an important role in
mediating and regulating short- and potentially long-term effects of drug use (for review, see
Nairn et al., 2004). For instance, acute treatment of cocaine has been found to increase the
phosphorylation of Thr-34 of DARPP-32 in the striatum (Nishi et al., 2000) and chronic
treatment is associated with decreased phosphorylation of Thr-34 (Bibb et al., 2001). Chien et al.
(2012) found that an acute treatment of METH (1 mg/kg, i.p.) increased DARPP-32
phosphorylation at Thr-34 and Thr-75 after an hour of injection. However, this increase in
DARPP-32 phosphorylation and METH-induced increased locomotor activity was attenuated by
naloxonazine, an opioid agonist, when injected prior to METH administration (Chien et al.,
2012). Chronic administration of METH (4 mg/kg, intracranial) over 14 days followed by a one7

week withdrawal showed a decreased basal phosphorylation of DARPP-32 at Thr-34 and
increased basal phosphorylation at Thr-75 (Chen & Chen, 2005).
Regions of Interest
Nucleus Accumbens
The nucleus accumbens has been considered as a major part of reward processing,
motivational behavior, locomotion, learning, and other biological drives necessary for survival.
The NAc can be divided into two sections: a central core and a surrounding shell. (for review,
see Salgadi & Kaplitt, 2015). Deutch and Cameron (1992) suggested that the nucleus accumbens
core (NAcc) might be more aligned with the striatum while the NAc shell is connected with the
mesolimbic pathway. Furthermore, other studies support that projections to the substantia nigra
rise from NAcc (Berendse et al, 1992), and VTA mainly innervates NAc shell (Gerfen et al.,
1987, as cited in Salgadi & Kaplitt, 2015). These findings suggest that while NAc shell might be
more associated with immediate reward processing, NAcc might be more involved in learning
and behavioral responses to rewarding properties. As discussed previously, drugs of abuse
increase DA influx in NAc and HPC through the mesolimbic pathway. Kleven et al., (1990)
found a decrease in D1 binding sites in NAc and striatum after a 2-week long cocaine treatment
(10 or 20 mg/kg) followed by either an immediate observation or after a 2-week withdrawal
period. Kang et al. (2016a) did not find any effect of chronic AMPH exposure (3mg/kg) on D1
expression in NAc, but there was a significant reduction in medial PFC. These differences could
be dose-dependent considering that NAc is less sensitive to DA-depleting changes (Cass, 1997).
As discussed earlier, drug effects on DARPP-32 in the striatum, which includes NAc, have been
examined thoroughly, with most findings suggesting an acute increase in DARPP-32
phosphorylation and basal decrease after chronic drug exposures. Although drug-induced
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changes in DARPP-32 expression in NAcc and shell has not been investigated separately, it is
known that persistent changes in drug-induced protein expression in the NAc occur in the core
rather than the shell (Miller & Marshall, 2005). This could be a result of different mechanisms of
reward processing associated with each section. Also, because DARPP-32 signaling has been
associated with psychomotor stimulation (Borgkvist et al., 2007), and NAcc is more associated
with motor and behavioral responses to rewarding stimuli, the current experiment will focus on
the DARPP-32 expression in NAcc.
Hippocampus and Perirhinal Cortex
Drugs of abuse are associated with disturbed learning as well as the development of
maladaptive memories between environmental cues and drug effects, which might play a role in
future drug use. Although acute effects of AMPHs include increased memory consolidation,
recall, and attention, chronic use is associated with impaired learning, memory, attention, and
decision making (for review, see Kutlu & Gould, 2016). These hippocampal effects might be a
result of DA activity. Because DA antagonists can block AMPH-induced conditioned place
preference (e.g., Bardo et al., 1999), it is possible that enhanced DA activity might be a cause of
hippocampal-learning impairments. It has been suggested that compared to other DA receptors,
DA D1 and D2 receptors may have a greater effect on hippocampal learning (for review, see
Berke & Hyman, 2000). DA receptors are most highly expressed in the dentate gyrus (DG),
CA1, and CA3 subregions of the HPC (Yokoyoma et al., 1995).
Both acute and repeated administrations of METH have been found to disrupt object
recognition memory in rats (Reichel et al., 2011; Schroder et al., 2003). Although both HPC and
perirhinal cortex (PRh) have been found to be associated with recognition memory, research has
shown that PRh is more concerned with differentiating familiarity, while HPC is concerned with
9

judging the likelihood of previous exposure (for review, see Brown & Aggleton, 2001). PRh,
which has high D1 and D2 DA receptor expression through all its layers, receives input from
CA1 and the subiculum of the HPC. This input has been shown to arrive at layers V and VI of
the perirhinal cortex (for review, see Kealy & Commins, 2011).
The Present Study
The purpose of the current experiment was to examine the long-term and persistent
effects of chronic METH self-administration on DA D1 and DARPP-32 levels in NAcc, HPC,
and PRh. The actions of METH seem to cause many short- and long-term alterations in the
mesolimbic system through influencing DA influx, DAT levels (Giros et al., 1996), DA
receptors (McCabe et al., 1987), and eventually DARPP-32 phosphorylation (Chen & Chen,
2005). Because most previous research has focused on the striatum, the effects on HPC and PRh
have not been thoroughly examined. However, previous research showed that METH has an
ability to disrupt recognition memory (e.g., Reichel et al., 2011), which might be associated with
some changes in recognition memory-related regions such as HPC and PRh.
Considering all the previous findings in the field, the chronic and persistent effects of
METH should be examined thoroughly because the long-term effects in the mesocorticolimbic
system could potentially encourage future drug use and behavioral disturbances (e.g., Kang et al.,
2016a). This could especially be true for adolescents as their brains are going through a series of
changes in many regions (for review, see Brenhouse & Andersen, 2011). Because DA D1
receptors and DARPP-32 in NAcc, HPC, and PRh might have significant roles in reward
processing, drug addiction, as well as memory impairment, the proposed study investigated the
long-term alterations in D1 receptors and DARPP-32 expression in rats that were exposed to
chronic self-administration of METH or saccharin to answer the following research questions.
10

Research Questions
Research Question 1: How does chronic administration of METH affect the density of
dopamine D1 receptors in the NAc, CA, and PRh? I predicted that chronic METH selfadministration would decrease the density of dopamine D1 receptors in NAc, CA, and PRh.
Research Question 2: How does chronic administration of METH affect the density of
DARPP-32 expression in the NAc, CA, and PRh? I predicted that chronic METH selfadministration would decrease the density of DARPP-32 in NAc, CA, and PRh.

11

CHAPTER II: METHODOLOGY
Subjects and Methamphetamine Treatment
Brain tissues were obtained from the laboratory of Dr. Joshua Gulley at University of
Illinois, Urbana-Champaign. The subjects were 3 male and 11 female (METH = 7, saccharin = 7)
Sprague-Dawley rats. Animals were housed on a reversed 12-hr light/dark cycle at their facility
with food and water available ad libitum. All training and testing were completed during the rats’
dark cycle. The experimental procedures were approved by the Institutional Animal Care and
Use Committee at the University of Illinois at Urbana-Champaign and were consistent with the
Guide for the Care and Use of Laboratory Animals (National Research Council, 2011). As
described in Westbrook et al. (2020), the experiment included two groups: adolescent-onset and
adult-onset METH exposure. Intravenous catheterization surgery was performed approximately
on P32 or P82, which was followed by a 5-day recovery and daily self-administration sessions of
METH and saccharin. Self-administration, which lasted from P41 to P62 or P91 to P112, was
stable across groups. During the short-access period, the first 7-days, the administration was
between 2-3 mg/kg per day. During the long-access days, remaining 14-days, it was
approximately between 8 and 10 mg/kg each day. After 19 days of abstinence and cognitive
tests, which included a novel object recognition task and object-in-place task, the animals were
anesthetized with 195 mg/kg pentobarbital and perfused transcardially with ice-cold saline. The
brains were removed, placed in chilled saline for 1 min, and dissected using a chilled metal brain
matrix. Tissues were stored at -80ºC until they were treated with 4% p-formaldehyde in 0.1M
phosphate buffer (PB) for 24 h and then stored in 20% sucrose for at least 3 days prior to
sectioning.
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In this experiment, I used 6 tissues (METH = 3, saccharin = 3) each for NAcc, HPC and
PRh staining. However, one of the subjects in the METH condition was excluded later due to
unsuccessful staining. Another METH subject in PRh was excluded because of an error in
sectioning. The final number of subjects for each region in the METH and saccharin groups are
listed in Table 1 with their age-of-onset of exposure.
Table 1
Number of Subjects in Each Condition
METH

Saccharin

Adult-Onset

Adolescent-Onset

Adult-Onset

Adolescent-Onset

NAc

2

1

0

2

PRh

1

1

1

2

HPC

2

1

1

2

Antibodies
The first D1DR antibodies used in initial D1 staining were selected from Stojanovic et al.
(2015). The primary antibody, monoclonal anti-D1 dopamine receptor antibody (#D2944) was
purchased from Sigma Aldrich (St. Louis, MO, USA). The AffiniPure Fab Fragment Goat AntiRat IgG (H+L) (#112-006-143) and the secondary antibody, peroxidase-conjugated AffiniPure
Donkey Anti-Goat IgG (H+L) (#705-035-147) were purchased from Jackson Immuno Research
(West Grove, PA, USA). For the second D1 staining, DRD1 Polyclonal antibody (17934-1-AP)
was obtained from Proteintech (Rosemont, IL, USA). DARPP-32 staining was completed using
13

the protocol by Smith et al. (2015), using a DARPP-32 primary antibody, rabbit anti-DARPP-32
(Abcam #40801) and a Vector Elite ABC kit by Vector Laboratories (Burlingame, CA, USA).
Immunohistochemistry
Brain tissues were sectioned either coronally or horizontally at a thickness of 40-μm
using a cryostat microtome. Every third section for each tissue was assigned to either primary
antibody, omit primary antibody, or cresyl violet-staining groups. Cresyl violet-stained sections
were used to examine the gross structure of the tissue and determine structure boundaries. Omit
primary antibody control sections, omits, went through the same immunostaining protocols as
the primary antibody sections except that they were incubated without the primary antibody to
control for non-specific tissue staining from the procedures. Sections were immediately mounted
on poly-l-lysine coated slides, which were prepared at least 30 min prior to mounting. At least 45
min after mounting, all sections in the primary antibody and omit primary antibody control
groups were washed three times for 10 min each in phosphate-buffered saline (PBS) to remove
formaldehyde, placed in methanol with 0.4% H2 O2 for 20 min to reduce endogenous peroxidase
activity, and washed again three times in PBS for 10 mins each. Then, sections were treated with
1% sodium borohydride in 0.1 M PB for 30 min to improve the staining, washed twice with PB
two times for 5 min each, and washed with PBS for 30 min.
For the initial D1 staining protocol, sections were treated with 1% goat serum and 0.3
Triton X-100 in PBS three times for 30 min each. Then, they were incubated with the primary
antibody, anti-D1DR, (1:200) and the fab fragment (1:100) for two days at 4℃ in 0.5% Triton
X-100 in PBS. The primary antibody and fab fragment were preincubated for 60 min before
treating sections to avoid cross-reactivity between the rat tissue and the primary antibody. After
two days, the sections were removed and washed three times in PBS for 10 min each. They were
14

placed in the secondary antibody for 60 min in 0.5% Triton X-100 in PBS followed by three PBS
washes for 10 min each.
For the second D1 staining protocol, sections were treated with 1% normal goat serum,
0.5% Triton X-100 in PBS for 60 min; 0.8% bovine serum albumin in PBS for 40 min; and
incubated overnight at 4℃ with the anti D1 antibody (1:500) in PBS with 0.5% Triton X-100.
The next day, sections were rinsed in PBS three times for 10 min each and treated with
biotinylated goat anti-rabbit secondary antibody (Vector Elite ABC kit) in PBS for 60 min. Then,
the sections were washed with PBS three times for 10 min each and treated with an ABC
peroxidase complex solution (Vector Elite ABC kit) for 60 min followed by another three PBS
washes for 10 min each.
For DARPP-32 staining, sections were treated with 1% normal goat serum and 0.2%
Triton X-100 in PBS for 30 min; and incubated overnight at 4℃ with the anti-DARPP-32
primary antibody (1:3000), 0.5% Triton-X, and PBS. The next day, sections were rinsed in PBS
three times for 10 min each and treated with biotinylated goat anti-rabbit secondary antibody in
PBS for 30 min. Then, the sections were washed with PBS three times for 10 min each and
treated with an ABC peroxidase complex solution (Vector Elite ABC kit) for 30 min followed by
another three PBS washes for 10 min each.
After the last step in each protocol, the sections were treated with 0.0005% 3,30diaminobenzidine (DAB) and 0.0001 H2 O2 in PBS for 2-4 min to create the insoluble brown
chromogen. The sections were washed with PBS three times for 10 min each and let to dry
overnight. After going through a series of ethanol and xylene washes, the slides were
coverslipped with DPX (Electron Microscopy Sciences, Hatﬁeld, PA, USA).
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Cresyl violet-staining tissues were washed in PBS and 0.1M PB for 10 min each and left
to dry overnight. After going through a series of ethanol and xylene washes, they were stained
with 0.1% cresyl violet solution and coverslipped with DPX.
Statistical Analyses
The analyzed sections were NAcc, Layer V of PRh, and subregions CA1, CA3, and DG
of HPC. Sections were chosen using the cresyl violet-stained samples for each subject. Examples
of each subregion can be seen in Figure 1. The antibody and omit sections were examined using
standard light microscopy (Leica Microsystems MZ9.5 and DMRBE microscopes, Buffalo
Grove, IL, USA). The photomicrographs were taken using a CCD camera (Leica Microsystems
DFC300FX) and the Image-Pro Express MC program (MediaCybernetics, Silver Spring, MD,
USA) on a Windows PC. Magnification used during these analyses was 200X for NAcc and
Layer V of PRh, and 400X for HPC subregions.
The differences between antibody and omit control groups were measured by
determining the measure of luminance, the intensity of light emitted from a tissue, as performed
in Butler et al., (2019). Darker staining leads to lower luminance values and lighter staining leads
to higher luminance values. Then, the difference between the luminance values of antibodystained sections and omits was calculated to find specific staining for each subject. In
comparison, a lower difference value between omit and antibody staining would mean less
specific staining. These values were compared through an independent samples t-test comparing
METH and saccharin groups.
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Figure 1
Cresyl Violet Staining

Note. (A) Nucleus accumbens core. Magnification 100X. (B) Layer V and VI of perirhinal
cortex. Magnification 100X. (C) Dentate gyrus of hippocampus. Magnification 200X. (D) CA1
of hippocampus. Magnification 200X. (E) CA3 of hippocampus. Magnification 200X.
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CHAPTER III: RESULTS
Dopamine D1 Histology
The initial D1 staining protocol resulted in high background staining in both primary
antibody and omit primary antibody control groups. The high level of non-specific staining could
not be reduced by several modifications to the procedure. The second D1 antibody staining
protocol, using the ABC method, was successful (Figure 2). There is a noticeable difference
between primary antibody and control groups, indicating the presence of specific D1 staining.
Unfortunately, there were not enough tissues to be processed to analyze the treatment effects.
Figure 2
D1 Staining in NAcc

Note. (A) Antibody staining; luminance value of 1573. Magnification 200X. (B) Omit;
luminance value of 1999. Magnification 200X.

DARPP-32 Histology
Nucleus Accumbens
The DARPP-32 staining protocol resulted in visibly different primary antibody and omit
primary antibody control staining (See Figure 3). Specific luminance values were calculated by
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taking the difference between values for antibody and control sections of each subject. Mean
specific luminance values of NAcc tissues for METH and saccharin groups were compared
through an independent samples t-test. The values of METH and saccharin groups were similar
(See Table 2). There was no significant effect of condition on the specific luminance values of
NAcc, t(3) = -1.76, p = .177. Antibody staining for each subject of the NAcc group can be found
in Appendix A.
Figure 3
DARPP-32 Staining in the NAcc

Note. METH group; adult-onset. (A) Antibody staining; luminance value of 1704. Magnification
200X. (B) Omit; luminance value of 2011. Magnification 200X.
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Table 2
Mean Specific Luminance Values for METH and Saccharin Groups in Each Subregion.
METH

Saccharin

M

SD

M

SD

NAcc

345.52

54.01

407.47

27.86

PRh

238.03

176.65

295.86

80.72

DG

131.81

52.72

221.31

123.89

CA1

120.42

43.53

217.23

109.68

CA3

74.82

47.06

203.32

114.73

Perirhinal Cortex
The DARPP-32 staining protocol resulted in visibly different antibody and omit staining
(See Figure 4). Mean specific luminance values of PRh tissues for METH and saccharin groups
were compared through an independent samples t-test. The values of METH and saccharin
groups were similar (See Table 2). There was no significant effect of condition on the specific
luminance values of PRh, t(3) = -0.52, p = .638. Antibody staining for each subject of the PRh
group can be found in Appendix B.
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Figure 4
DARPP-32 Staining in the PRh

Note. METH group; adolescent-onset. (A) Antibody staining; luminance value of 1623.
Magnification 200X. (B) Omit; luminance value of 1968. Magnification 200X.

Hippocampus
The DARPP-32 staining protocol resulted in visibly different antibody and omit staining
(See Figure 5). Mean specific luminance values of HPC subregions for METH and saccharin
groups were compared through independent samples t-tests. The values of METH and saccharin
groups were similar in each subregion (See Table 2). There was no significant effect of condition
on the specific luminance values of DG, t(4) = -1.15, p = .314, CA1, t(4) = -1.42, p = .228, or
CA3, t(4) = -1.79, p = .147. Antibody staining for each subject of the HPC subregions can be
found in Appendix C.
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Figure 5
DARPP-32 Staining in the HPC

Note. METH group; adult-onset. (A) Antibody staining in CA1; luminance value of 1688.
Magnification 400X. (B) Omit staining in CA1; luminance value of 1846. Magnification 400X.

Because there were not any differences between METH and saccharin groups, I
examined the effect of age-of-onset on DARPP-32 expression for HPC subjects. In DG, specific
luminance values for the adult-onset group (M = 159.6, SD = 30.38) were comparable to the
adolescent-onset group (M = 185.04, SD = 124.48). These values were not significantly different,
t(4) = -0.27, p = .801. In CA1, specific luminance values for the adult-onset group (M = 144.26,
SD = 19.5) were comparable to the adolescent-onset group (M = 181.11, SD = 115.06). These
values were not significantly different, t(4) = -0.42, p = .693. In CA3, specific luminance values
for the adult-onset group (M = 95.41, SD = 43.42) were comparable to the adolescent-onset
group (M = 160.9, SD = 126.39). These values were not significantly different, t(4) = -0.68, p =
.535.
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CHAPTER IV: DISCUSSION
Repeated administration of METH has been shown to influence levels of D1 receptors
(e.g., McCabe et al., 1987) and DARPP-32 (e.g., Chen & Chen, 2005) expression in the rat brain.
Previous experiments that used D1 receptor (Ares-Santos et al., 2012) and DARPP-32
(Zachariou et al., 2006) knock-out mice illustrated that both D1 and DARPP-32 might be
required for the action effects of drugs. Because most studies in the past targeted only the
striatum, this experiment was designed to investigate the chronic effects of METH on D1
receptor and DARPP-32 expression levels in NAcc, PRh, and HPC. However, the results of D1
staining were inconclusive, and the hypothesis on DARPP-32 was not supported. The results
showed that there were no differences between DARPP-32 staining of METH and saccharin
subjects, which implies that METH did not have a chronic effect on DARPP-32 expression.
The first procedure used for D1 staining was unsuccessful and resulted in similarly
stained antibody and omit control groups. To troubleshoot this issue, I decreased the primary
antibody concentration to 1:250, 1:500, 1:1000, and 1:2000; however, the results did not change.
This could be because the antibodies selected were rat primary antibodies, which is often
complicated by high background staining. Although I used a Fab fragment to block endogenous
immunoglobulins by incubating it with the primary antibodies, it is possible that this method is
not as effective as indirect staining with an antibody raised in another animal in reducing nonspecific binding. Following this procedure, I also tried blocking the tissues with Fab fragment
prior to incubating with the primary antibody as advised by the seller; however, this method did
not yield to any promising results either. The second D1 primary antibody coupled with the ABC
method resulted in better results. The antibody-stained tissues were visibly darker than omit
tissues. However, because of time restrictions and limited resources, I was unable to stain
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enough tissues for this project. Future studies may benefit from selecting the latter procedure
when staining for D1 receptors in rat brain.
To answer the second research question, I examined the effects of METH selfadministration on each brain region. Although the mean specific luminance values for METH
groups were lower, which means that they had lower levels of staining, there were no significant
differences between conditions for any of the subregions. These findings may not support the
previous research that illustrated significant chronic DARPP-32 alteration in rat striatum (e.g.,
Chen & Chen, 2005), but they align with the results of Westbrook et al. (2020), in which the
analyses showed no difference on D1 receptor expression levels in either PFC or NAc between
METH and saccharin groups. Because DARPP-32 is co-localized with D1 receptors, one might
expect DARPP-32 levels to be unaffected when the number of D1 receptors are not altered.
The conflicting results between previous research and the current experiment could also
be because of differences in methodology. While Westbrook et al. (2020) utilized selfadministration of METH and saccharin, most previous studies used experimenter-delivered
injections of METH and saline. It is possible that self-administration of saccharin, which was at a
comparable rate to METH self-administration, might be similarly rewarding. For instance,
Hajnal et al. (2004) found that sucrose intake increases DA levels in NAc. In addition, it has
been illustrated that saccharin can suppress the rewarding properties of cocaine after a long-term
cocaine treatment (Lenoir et al., 2007). Also, in animal models of food addiction, saccharin
intake has been found to be increased via opioid agonists (Zhang & Kellyer, 2002) and decreased
via opioid antagonists (MacDonald et al., 2003). Similarly, Chien et al. (2012) found that
pretreatment with opioid antagonists can attenuate METH-induced locomotor activity as well as
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DARPP-32 phosphorylation. Overall, the similarities between the rewarding properties of drugs
and sweet-tasting substances may have influenced our results.
Visual examination of the HPC of each subject illustrate an apparent difference in the
DARPP-32 staining between adult-onset subjects in the METH group compared to adult-onset
subjects in the saccharin group, while the difference between the adolescent-onset groups is less
noticeable. However, because of the small sample size, I was unable to examine the potential
relationship between the age-of-onset and drug condition. It is possible that chronic METH
administration could have different effects with different age-of-onset exposures. Ultimately,
there were no overall differences between adult-onset and adolescent-onset groups on the
specific staining values.
Along with the small sample size, the current experiment had other important limitations.
Brain tissues used in this experiment were originally dissected to be analyzed with methods other
than immunohistochemistry. Typically, in an anatomical research project, brains from subjects
would be processed as whole-brain sections. Because I used dissected brain regions rather than
whole brains, it was not possible to section and mount them all comparably. Also, because the
dissected brain regions provided no structural information of the exact location, I was unable to
determine while analyzing the PRh pieces whether the selected tissues were from the same dorsal
and ventral coordinates. Although the PRh analyses focused on Layer V, it is possible that the
selected sections could have been cut from very different coordinates of the region. Similarly,
when selecting HPC pieces, I was unable to use tissues from the same exact coordinates due to
technical issues such as tissues being lost while being processed or having random tears and
artifacts. Lastly, the luminance value analysis used in this experiment intended to measure
specific staining by comparing antibody and omit tissues. The difference between antibody and
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omit tissue values represented the intensity of DARPP-32 expression. It is possible that if the
tissues were examined through cell counting, the results could differ. However, the luminance
value analysis used in this experiment might be a more reliable procedure considering that
visualization and quantifying of stained cells would be more difficult and potentially biased.
Using luminance values rather than cell counting allows to account for all DARPP-32 specific
staining even if cells with DARPP-32 immunoreactivity may not be clearly visible.
The questions such as whether METH had a chronic effect on D1 and DARPP-32
expression and whether there is a relationship between age-of-onset and drug-induced long-term
changes remain to be clarified. Future studies could implement a similar design with a larger
sample size and potentially with a more neutral control substance for self-administration. The
differences between the effects of self-administration and experimenter-administration should
also be thoroughly examined.
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APPENDIX A: DARPP-32 ANTIBODY STAINING ON NUCLEUS ACCUMBENS

Note. The values represent individual luminance values for specific staining calculated by taking
the difference between omit primary controls and primary antibody values. Magnification 200X.
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APPENDIX B: DARPP-32 ANTIBODY STAINING ON PERIRHINAL CORTEX

Note. The values represent individual luminance values for specific staining calculated by taking
the difference between omit primary controls and primary antibody values. Magnification 200X.

40

APPENDIX C: DARPP-32 ANTIBODY STAINING ON HIPPOCAMPUS

Note. DG Staining. The values represent individual luminance values for specific staining
calculated by taking the difference between omit primary controls and primary antibody values.
Magnification 400X.
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Note. CA1 Staining. The values represent individual luminance values for specific staining
calculated by taking the difference between omit primary controls and primary antibody values.
Magnification 400X.
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Note. CA3 Staining. The values represent individual luminance values for specific staining
calculated by taking the difference between omit primary controls and primary antibody values.
Magnification 400X.
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